免疫反应在NAFLD相关肝癌发生中的作用及治疗调控前景
综述概述NAFLD/NASH相关炎症与发病机制,重点讨论CD8+CXCR6+PD1+T细胞在NASH向HCC转变中的作用,并讨论阻止疾病进展至肝癌的预防措施及NASH-HCC患者的管理策略。
要点
- 慢性脂肪变性诱导的CD8+CXCR6+PD1+T细胞以非抗原依赖方式清除实质与非实质细胞,促进慢性肝损伤和促肿瘤环境。
- CD8+CXCR6+PD1+T细胞具有耗竭、过度活化、驻留表型,触发NASH向HCC转变,并可能与对免疫检查点抑制剂(特别是阿替利珠单抗/贝伐珠单抗)反应较弱有关。
- NAFLD相关HCC最常发生在慢性炎症和肝硬化肝脏背景下,肠道微生物群及其代谢产物等环境因素参与NAFLD-NASH复杂病理生理。
核心结论
- 基于对病理生理机制的理解,特异性靶向代谢通路以预防或减缓NAFLD向肝癌进展将成为可能。
研究设计与样本
- 综述:概述NASH相关炎症/发病机制,聚焦T细胞作用的新发现,讨论预防疾病进展至肝癌的措施及NASH-HCC患者的管理策略。
主要发现
- 慢性脂肪变性诱导的CD8+CXCR6+PD1+T细胞以非抗原依赖方式清除实质与非实质细胞,促进慢性肝损伤和促肿瘤环境。
- CD8+CXCR6+PD1+T细胞具有耗竭、过度活化、驻留表型,触发NASH向HCC转变,并可能与对免疫检查点抑制剂(特别是阿替利珠单抗/贝伐珠单抗)反应较弱有关。
- NAFLD相关HCC最常发生在慢性炎症和肝硬化肝脏背景下。
- NAFLD-NASH的复杂病理生理反映在环境因素中,特别是肠道微生物群及其代谢产物。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The liver is the central metabolic organ of the body, regulating energy and lipid metabolism, while also having potent immunological functions. Overwhelming the metabolic capacity of the liver via obesity and a sedentary lifestyle leads to hepatic lipid accumulation, chronic necro-inflammation, enhanced mitochondrial/endoplasmic reticulum stress and development of non-alcoholic fatty liver disease (NAFLD), and its more severe form non-alcoholic steatohepatitis (NASH). Based on an improved understanding of pathophysiological mechanisms, specifically targeting metabolic pathways to prevent or slow down the progression of NAFLD to liver cancer will become possible. Genetic/environmental factors are also known to contribute to the development of NASH and progression to liver cancer. The complex pathophysiology of NAFLD-NASH is reflected by environmental factors, particularly the gut microbiome and its metabolic products. NAFLD-associated HCC most often occurs in the context of a chronically inflamed and cirrhotic liver. Recognition of environmental alarmins or metabolites derived from the gut microbiota and the metabolically injured liver create a strong inflammatory milieu supported by innate and adaptive immunity. Several recent studies indicate that chronic steatosis induces auto-aggressive CD8+CXCR6+PD1+ T cells that eliminate parenchymal and non-parenchymal cells in an antigen-independent manner. This promotes chronic liver damage and a pro-tumorigenic environment. CD8+CXCR6+PD1+ T cells possess an exhausted, hyperactivated, resident phenotype; they trigger the NASH to HCC transition and might be responsible for weaker responses to immune checkpoint inhibitors - in particular atezolizumab/bevacizumab. Here, we provide an overview of NASH-related inflammation/pathogenesis, focusing on new discoveries on the role of T cells. This review discusses preventive measures to halt disease progression to liver cancer and therapeutic strategies to manage patients with NASH-HCC.
引用
- Yahoo N, Dudek M, Knolle P, et al. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation. J Hepatol. 2023. PMID: 36893854. doi:10.1016/j.jhep.2023.02.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。